new treatment for prostate carcinoma. Naphthoquinone analogs such as plumbagine, pharmaceutical compositions comprising naphthoquinone analogs such as plumbagine, and methods of treating diseases and / or conditions such as cancer with naphthoquin analogs such as plumbagine are described herein. ...
In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma. Image credit: freshidea | stock.adobe.com During a presentation at the National Comprehensive Cancer Network Annual 2024 Conference in Orlando, ...
In recent years the pace of research in prostate cancer has increased dramatically. Creative ideas in combination with new and emerging technologies have led to an explosion of discovery. These types of advances in prostate cancer research presage an era of new treatment strategies based on an unde...
Prostate cancer is a devastating disease that will be diagnosed in approximately 200,000 men in 2001. New methods for screening, prevention, and treatment are being developed. In addition, novel agents for the treatment of resistant prostate cancer are being developed in clinical trials. This revie...
(Hatashima et al.2022). The C481S mutation of BTK is the most common resistance mechanism restricting the treatment efficacy of covalent BTK inhibitors (Naeem et al.2023). The next-in-class small moleculepirtobrutinibis an oral, potent, highly selective, and noncovalent BTK inhibitor ...
New Treatment Option In The Fight Against Prostate Cancer - Implant Gives Men Flexibility In Treatment Choices
We next determined whether targeting the BMM could reduce the development of pre-B ALL. Given that osteoclasts are key effectors of leukemia-induced bone loss in our model, we assessed the efficacy of zoledronic acid, an osteoclast inhibitor, with treatment starting on Day 3 post leukemia cell ...
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer. 来自 掌桥科研 喜欢 0 阅读量: 25 作者: Laurent Boccon-Gibod,Peter Iversen,Bo-Eric Persson 摘要: Gonadotrophin-releasing hormone (GnRH) receptor blockers (antagonists) are the latest addition to the hormonal ...
Although conventional modalities predominate in sarcoma treatment, new approaches to target aberrant signalling with specific therapies, overcome acquired resistance and target unconventional pathways are rapidly evolving.Abstract Increasingly, human mesenchymal malignancies are being classified by the abnormalities ...
The LancetCommission on prostate cancer argues that the "informed choice" program for prostate cancer screening with PSA testing, which is common in high-income countries, may lead to over-testing and unnecessary treatment in older men, and under-testing in high-risk younger men. The authors adv...